Table 4.
Polymer | Targeting ligand | Conjugation method | Average size (nm) |
Zeta potential (mV) |
Applications | Reference |
---|---|---|---|---|---|---|
PEGylated PLGA | A10 aptamer | Covalent conjugation | 188 | N/A | Targeting human xenograft prostate cancer in mice | [93] |
| ||||||
PLGA-PEG | — | Covalent conjugation | 170 | N/A | NPs encapsulating endostar slowed growth of tumor xenografts | [94] |
| ||||||
PEGylated PLGA | cLABL | Covalent conjugation | 244 | −23.3 | Targeting the vascular endothelium with upregulated ICAM-1 | [95] |
| ||||||
50/50 PLGA and Palmitate-Avidin | Biotinylated PEG, and horseradish peroxidase | Streptavidin-biotin noncovalent binding | 170 | −11.3 | Diffusion of PEGylated particles cervical mucus was 3–10x higher than unmodified PLGA | [96] |
| ||||||
PLGA-PEG | — | Covalent conjugation | 148 | 1.84 | Sustained release of 9-nitrocamptothecin | [97] |
| ||||||
PLGA-PEG | Covalent conjugation | 65–100 | N/A | Sustained release of adriamycin | [98] | |
| ||||||
PLA-PEG | Covalent conjugation | 952 | Neutral | Reduced opsonization of NPs | [99] | |
| ||||||
PLGA and PEG-distearyl Phosphoethanolamine (PEGPE) |
Coemulsification | 20–40 | −19.2 | Higher Doxorubicin encapsulation efficiency, slower release rate, and rapid cellular uptake | [100] | |
| ||||||
PLGA-mPEG | Covalent conjugation | N/A | N/A | Reduction in protein adsorption on the surface films of PLGA-PEG (750 and 2000) compared to adsorption onto PLGA only | [101] | |
| ||||||
PLGA | PEG/poloxamer 407 | Coincorporation or surface adsorption | 189–225 | (−16.1)–(−20.3) | Increased blood circulation half-life of NPs | [102] |
| ||||||
PLGA-PEG di-block (15% PEG with 5 kDa) | Covalent conjugation | 114 | −2.8 | Higher cellular uptake of formulations containing 15% of PEG compared to 5% and 10% PEG-PLGA formulations | [103] |